Despite updated guidelines for universal hepatitis C virus screening in pregnancy, testing rates remain well below targets, missing chances to prevent perinatal transmission.
Erica Kaufman West, MD, FIDSA, highlighted in the Infectious Diseases Society of America Science (IDSA) Speaks blog that despite updated universal screening guidelines for
Since the 1990s, the opioid epidemic has driven a surge in HCV infections, increasingly affecting younger populations, including women of childbearing age. Historically, HCV was mostly detected in baby boomers, but now, new infections are rising among pregnant individuals, raising concerns for mother-to-child transmission.2
Updated Screening Recommendations
In response, major public health organizations have revised screening recommendations. The Centers for Disease Control and Prevention updated guidelines in 2020 to recommend universal HCV screening for all pregnant individuals during each pregnancy, extending beyond the prior risk-based approach. The American College of Obstetricians and Gynecologists followed suit, issuing a practice advisory in May 2021 endorsing HCV screening during the first prenatal blood assessment in every pregnancy.3 Similarly, the Society for Maternal-Fetal Medicine recommends universal antibody testing for HCV in all pregnant patients.4
Screening Trends and Findings
A recent analysis published in
Key findings include:
The study authors emphasize that although progress is evident, testing remains suboptimal. The perinatal period represents a critical health care touchpoint that should be leveraged for universal HCV diagnosis and linkage to care.5
Universal HCV screening during pregnancy is recommended by major health organizations but testing rates remain below 40%.
The opioid epidemic has shifted hepatitis C infections toward younger pregnant individuals, increasing the risk of mother-to-child transmission.
No approved HCV treatments exist for use during pregnancy, highlighting the importance of postpartum care and infant monitoring.
The Challenge of Treatment During Pregnancy
Currently, no HCV treatment is approved by the US Food and Drug Administration for use during pregnancy, although ongoing research explores the safety and efficacy of direct-acting antiviral therapies in this population. The American Association for the Study of Liver Diseases, IDSA, and the European Association for the Study of the Liver support considering treatment in pregnancy under clinical trial settings and recommend reporting such cases to the TiP-HepC Registry.6
In the meantime, obstetric providers are urged to connect pregnant individuals with positive test results for HCV with postpartum HCV care to initiate treatment after delivery and breastfeeding. Pediatric providers must be informed of maternal HCV status to ensure appropriate infant testing and follow-up.6
Public Health Implications
Hepatitis C infection can remain asymptomatic for years, with approximately 75% to 85% of infected individuals unaware of their status. Vertical transmission occurs in approximately 6% of infants born to infected mothers and is associated with adverse fetal outcomes, including low birth weight and fetal growth restriction.2,4
The high rates of HIV screening during pregnancy demonstrate that universal infectious disease screening in this setting is achievable. Stakeholders agree that innovative strategies and systems-level changes are urgently needed to improve HCV screening rates and ensure timely treatment, ultimately advancing toward the national goal of hepatitis C elimination.5
